Mapping the Mind: In Vivo Imaging of Synaptic Plasticity with HaloTag® Ligands

Posted on by Simon Moe

The brain is constantly rewiring itself, fine-tuning connections that shape how we think, learn, and remember. But capturing those fleeting molecular changes as they happen — at the level of individual synapses and across entire brain regions — has long been a challenge in neuroscience. Now, thanks to recent advances in HaloTag® dye technology, researchers can visualize protein dynamics in living brains with stunning clarity and specificity.

Continue reading “Mapping the Mind: In Vivo Imaging of Synaptic Plasticity with HaloTag® Ligands”

Bioluminescence vs. Fluorescence: Choosing the Right Assay for Your Experiment 

Posted on by Anna Bennett

From enzyme activity to gene expression, light-based assays have become foundational tools in life science research. Among these, fluorescence and bioluminescence are two of the most widely-used approaches for detecting and quantifying biological events. Both rely on the emission of light, but the mechanisms generating that light—and the practical implications for experimental design—are quite different. 

Choosing between a fluorescence or bioluminescence assay isn’t as simple as picking between two reagents off the shelf. Each has strengths and limitations depending on the application, instrumentation, and biological system. In this blog, we’ll walk through how each method works, where they shine (and where they don’t), and what to consider when deciding which approach is right for your experiment. 

Continue reading “Bioluminescence vs. Fluorescence: Choosing the Right Assay for Your Experiment “

Immune Surveillance Meets Innovation: The Critical Need for dsRNA Detection

Posted on by Promega

Today’s blog is written by guest blogger, Kai Hillman, Associate Product Marketing Manager at Promega.

RNA therapeutics have revolutionized modern medicine, offering groundbreaking solutions for diseases that were once deemed untreatable. These innovative treatments harness the power of RNA molecules to correct genetic anomalies and modulate protein expression, paving the way for personalized medicine. Among the many facets of RNA biology, double-stranded RNA (dsRNA) plays a pivotal role in cellular processes and immune surveillance.

Continue reading “Immune Surveillance Meets Innovation: The Critical Need for dsRNA Detection”

Beyond Ozempic: The New Frontier of Obesity Research

Posted on by Promega

Today’s blog is written by guest blogger, Alden Little, Marketing Intern at Promega.

From genetics to gut microbes, scientists are finding new ways to make white fat act like calorie-burning brown fat. Here’s how three research teams are working to find the next breakthrough obesity treatment.

Rethinking Fat: How New Research is Transforming Obesity Science

Obesity affects millions worldwide and remains a complex challenge shaped by diet, environment, genetics, and socio-economic factors. While medications like semaglutide have shown promise in supporting weight loss, there’s growing interest in alternative strategies.

One area gaining traction is adipose tissue biology. Adipose tissue—commonly known as body fat— is not just a passive storage site for excess energy, but an active player in regulating metabolism and energy balance. Adipose tissue comes in several forms:

  • White
  • Brown
  • Beige

Most of the fat in our bodies is called white adipose tissue (WAT). It stores energy for later use—but too much of it increases the risk for obesity, diabetes, and other health problems. In contrast, brown adipose tissue (BAT) burns energy to generate heat through a process called thermogenesis, helping regulate body weight and temperature. Scientists have discovered a third kind, called beige adipose tissue, which behaves like BAT but can form within WAT under certain conditions like cold exposure or specific molecular triggers.

Continue reading “Beyond Ozempic: The New Frontier of Obesity Research”

Measles and Immunosuppression—When Getting Well Means You Can Still Get Sick

Posted on by Kelly Grooms
26062330-March-7-Kelly-600x900-WEB

In 2000 measles was officially declared eliminated in the United States (1), meaning there had been no disease transmission for over 12 months. Unfortunately, recent years have shown us it was not gone for good. So far in 2025 there have been 6 outbreaks and 607 cases. Five hundred and sixty-seven of these cases (93%) are associated with an outbreak; seventy-four (12%) cases have resulted in hospitalization, and there has been one confirmed death, with another death under investigation (as of April 3, 2025; 2).  For comparison, there were two hundred and eighty-five total cases in 2024; one hundred and ninety-eight (69%) were associated with outbreaks; one hundred and fourteen (40%) cases resulted in hospitalization. There were no deaths (2).  

Help in Limiting a Dangerous Childhood Disease

Before the development of a vaccine in the 1960s, measles was practically a childhood rite of passage. This common childhood disease is not without teeth however. One out of every 20 children with measles develops pneumonia, 1 out of every 1,000 develops encephalitis (swelling of the brain), and 1 to 3 of every 1,000 dies from respiratory and neurological complications (3). In the years before a vaccine was available, it is estimated that there were between 3.5 and 5 million measles cases per year. (4). The first measles vaccine was licensed in the U.S. by John Enders in 1963, and not surprisingly, after the measles vaccine became widely used, the number of cases of measles plummeted. By 1970, there were under 1,000 cases (2).

Decreased Childhood Mortality from Other Infectious Diseases—An Unexpected Benefit

Surprisingly, with the disappearance of this childhood disease the number of childhood deaths from all infectious diseases dropped dramatically. As vaccination programs were instituted in England and parts of Europe, the same phenomenon was observed. Reduction or elimination of measles-related illness and death alone can’t explain the size of the decrease in childhood mortality. Although measles infection is associated with suppression of the immune system that will make the host vulnerable to other infections, these side effects were assumed to be short lived. In reality, the drop in mortality from infectious diseases following vaccination for measles lasted for years, not months (5).

Continue reading “Measles and Immunosuppression—When Getting Well Means You Can Still Get Sick”

What 32,000 3D Spheroids Revealed About Culture Conditions

Posted on by Shannon Sindermann
3D Spheroid Cell Culture

Three-dimensional (3D) cell culture systems have become essential tools in cancer research, drug screening and tissue engineering—offering a more physiologically relevant alternative to traditional 2D cultures, which often fail to replicate key in vivo microenvironment features. But as the field has evolved, variability in experimental outcomes has become a key challenge, limiting their reproducibility and translation into clinical settings. While spheroids offer layered architecture, nutrient gradients and multicellular interactions, inconsistent culture methods have made it difficult to draw reliable conclusions across labs.

Continue reading “What 32,000 3D Spheroids Revealed About Culture Conditions”

The Long Road to a Norovirus Vaccine: How Close Are We?

Posted on by Sara Christenson

This winter, norovirus outbreaks surged across the U.S., with cases nearly doubling from last year, according to the CDC. Schools, cruise ships, nursing homes and healthcare facilities saw widespread illness, underscoring the urgent need for a norovirus vaccine.

Each year, norovirus causes 685 million infections worldwide and is the leading cause of foodborne illness in the U.S., responsible for 21 million cases annually. Despite its massive impact, there is still no approved vaccine—but recent advancements suggest that this could change.

Continue reading “The Long Road to a Norovirus Vaccine: How Close Are We?”

One Health and H5N1: Promega’s Commitment to Holistic Solutions

Posted on by Promega

The global outbreak of highly pathogenic avian influenza A (H5N1) underscores the critical importance of proactive and integrated health strategies. With its zoonotic potential, the H5N1 virus affects diverse animal populations and poses significant risks to human health, ecosystems, and economies worldwide. At Promega, we are dedicated to equipping researchers and public health professionals with the tools they need to navigate and address these complex challenges.

Understanding H5N1 and Its Impact

A Global Challenge

The H5N1 outbreak has led to the depopulation of over 300 million birds across 108 countries, spanning five continents. The virus has infected over 500 bird species and at least 70 mammalian species, including endangered California condors and polar bears (1). The virus has had significant economic repercussions, particularly in the poultry industry, with 168 million birds culled in the United States to date (2). Recent human infections, primarily among farm workers, highlight the need for continued vigilance and robust surveillance systems.

The One Health initiative takes a holistic approach to managing disease outbreaks such as bird flu.
Continue reading “One Health and H5N1: Promega’s Commitment to Holistic Solutions”

Advancing Neurodegenerative Disease Modeling: A Novel iPSC-Based Luminescence System for Parkinson’s Disease Research

Posted on by Amy Landreman

Advancing our understanding of neurodegenerative diseases requires model systems that faithfully recapitulate the biology of human neurons. A recent study by Gandy et al. in the International Journal of Molecular Sciences introduces an innovative luminescence-based platform to explore the role of Parkinson’s disease (PD)-associated genes in living cells. By leveraging human induced pluripotent stem cells (iPSCs) and CRISPR-mediated endogenous tagging, researchers at the Early Drug Discovery Unit at The Neuro (Montreal Neurological Institute-Hospital) at McGill University and Health Canada have created a powerful system for investigating protein expression and function in a physiologically relevant setting.

Continue reading “Advancing Neurodegenerative Disease Modeling: A Novel iPSC-Based Luminescence System for Parkinson’s Disease Research”

Bringing Science to Life: How Art and Sustainability Shape Our New Trade Show Booth Design

Posted on by Riley Bell

Step inside a Promega booth and leave the ordinary behind. Here, science sparks creativity, sustainability is woven into every detail, and discovery isn’t just something you see—it’s something you feel.

Continue reading “Bringing Science to Life: How Art and Sustainability Shape Our New Trade Show Booth Design”